Invitrogen, Agilent to co-market microfluidics system

April 8, 2005 — Invitrogen Corp. and Agilent Technologies Inc. announced a two-year agreement to co-market the PathAlert Detection System, a screening and confirmatory detection system for infectious agents.

The system is intended for use by government, military and research organizations for detection of infectious agents such as Bacillus anthracis (anthrax), Yersinia pestis (plague), Vaccinia (smallpox simulant) and Francisella tularensis (tularemia) in samples collected from the air, food and water.

The system includes Invitrogen’s PathAlert Detection Kits and the Agilent 2100 bioanalyzer or 5100 Automated Lab-on-a-Chip Platform. It will be distributed by Invitrogen.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.